RGNX is focused on developing, commercializing and licensing recombinant adeno-associated virus gene therapy with a proprietary delivery platform to treat rare diseases. RGNX is commercializing gene therapy products administered directly into the body, or in vivo, based on a NAV Technology Platform. Its NAV Technology Platform is currently being applied in the development of 23 product candidates for a variety of diseases, Regenxbio said, with exclusive rights to over 100 patents and patent applications worldwide.
January 30, 2023
RegMed Investors’ (RMi) closing bell: who said economics don’t matter?
January 25, 2023
RegMed Investors’ (RMi) closing bell: sector finishes down yet, made strides late in session
January 24, 2023
RegMed Investors’ (RMi) closing bell: inclining positive session, yet … wait and watch
January 23, 2023
RegMed Investors’ (RMi) closing bell: sector nudges higher
January 18, 2023
RegMed Investors’ (RMi) closing bell: momentum rolls downhill as economic data exchanges the scenario to a negative close
January 17, 2023
RegMed Investors’ (RMi) closing bell: share pricing slips on the icy surface as the sector dives
January 12, 2023
RegMed Investors’ (RMi) closing bell: cell/gene therapy sector appreciated in recent sessions as CPI report confirmed a weakening inflation trend
January 11, 2023
RegMed Investors’ (RMi) closing bell: sector gains, follow Tuesday’s advances post Monday’s pain
January 10, 2023
RegMed Investors’ (RMi) closing bell: the sector experiences a tailwind with the merry-go-round still spinning tomorrow
January 10, 2023
RegMed Investors’ (RMi) pre-open: after a lackluster first day at JPM23 with smaller attendance, NO masks and a diving sector
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.